Your browser is no longer supported. Please, upgrade your browser.
Settings
BHVN Biohaven Pharmaceutical Holding Company Ltd. daily Stock Chart
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-6.20 Insider Own6.90% Shs Outstand44.30M Perf Week6.81%
Market Cap2.84B Forward P/E- EPS next Y-5.22 Insider Trans-12.89% Shs Float34.48M Perf Month25.86%
Income-240.90M PEG- EPS next Q-1.22 Inst Own91.70% Short Float9.51% Perf Quarter78.52%
Sales- P/S- EPS this Y-23.00% Inst Trans0.74% Short Ratio5.71 Perf Half Y79.07%
Book/sh3.69 P/B17.34 EPS next Y11.40% ROA-113.30% Target Price67.06 Perf Year135.47%
Cash/sh5.96 P/C10.73 EPS next 5Y- ROE-217.40% 52W Range25.60 - 64.54 Perf YTD73.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.79% Beta-
Dividend %- Quick Ratio13.90 Sales past 5Y- Gross Margin- 52W Low147.60% ATR2.81
Employees63 Current Ratio13.90 Sales Q/Q- Oper. Margin- RSI (14)72.59 Volatility4.72% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-78.50% Profit Margin- Rel Volume0.72 Prev Close64.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume574.51K Price63.38
Recom1.80 SMA2017.51% SMA5027.31% SMA20059.03% Volume266,668 Change-0.96%
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Apr-16-19 08:10AM  The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 08:43AM  Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks
Apr-12-19 06:24PM  Here's Why Biohaven Pharmaceutical Jumped 20% Today Motley Fool +19.96%
06:14PM  CBX: Strong earnings for financials a good start CNBC Videos
04:30PM  General Electric, Biohaven Pharmaceutical Holding, Tesla and More Are Trending Insider Monkey
Apr-03-19 07:30AM  Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience PR Newswire
Apr-01-19 07:30AM  Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine PR Newswire
Mar-18-19 07:30AM  Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application PR Newswire
Mar-14-19 07:15PM  Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares GuruFocus.com
12:52PM  Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash? Simply Wall St.
07:30AM  Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole PR Newswire
Mar-13-19 07:30AM  Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant PR Newswire
Mar-05-19 07:40AM  Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding New Research Emphasizes Economic Growth GlobeNewswire
Feb-28-19 04:30PM  Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results PR Newswire
Feb-21-19 10:00AM  What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now? Zacks
Feb-20-19 07:30AM  Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole PR Newswire
Feb-19-19 07:30AM  Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy PR Newswire
Feb-04-19 07:30AM  Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist PR Newswire
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
03:00AM  Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy PR Newswire
Jan-07-19 03:00AM  Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China PR Newswire
Jan-03-19 07:30AM  Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.34%
Dec-17-18 07:08PM  Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Dec-12-18 10:56PM  Biohaven Announces Pricing of Public Offering of Common Shares PR Newswire
Dec-10-18 07:19PM  Biohaven Announces Proposed Public Offering of Common Shares PR Newswire
03:00AM  Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study PR Newswire
Dec-03-18 03:00AM  Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine PR Newswire +25.39%
Nov-29-18 08:09AM  The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga
Nov-28-18 04:00PM  Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary PR Newswire
Nov-27-18 08:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes New Research Emphasizes Economic Growth GlobeNewswire -7.69%
Nov-26-18 03:00AM  Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Nov-20-18 03:00AM  Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018 PR Newswire
Nov-15-18 03:00AM  Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant PR Newswire
Nov-14-18 04:06PM  Migraine-Focused Biotech Has A Headache On Quarterly Losses Investor's Business Daily -8.73%
03:00AM  Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results PR Newswire
Nov-13-18 08:30AM  Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies PR Newswire
Oct-22-18 03:00AM  Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist PR Newswire
Oct-10-18 02:42PM  Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-09-18 03:00AM  Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut PR Newswire
Sep-12-18 06:19AM  Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine PR Newswire +6.40%
03:00AM  Biohaven Appoints Bob Repella to Board of Directors PR Newswire
Sep-06-18 03:00AM  Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine PR Newswire
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
03:00AM  Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy PR Newswire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga +5.95%
Aug-14-18 04:15PM  Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results PR Newswire
Aug-01-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire
03:00AM  First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial PR Newswire
Jul-31-18 07:15AM  Free Stock Performance Review on Biogen and Three Additional Biotech Stocks ACCESSWIRE
Jul-24-18 03:00AM  Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease PR Newswire
Jun-28-18 12:30PM  Biohaven Pharma's New Migraine Drug Shows Promise in Late-Stage Test Results TheStreet.com
07:20AM  Free Technical Reports on Cerus and Three Additional Biotech Equities ACCESSWIRE
03:00AM  Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting PR Newswire
Jun-21-18 07:15AM  Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma ACCESSWIRE
Jun-19-18 08:37AM  Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Is Expected To Breakeven Simply Wall St.
Jun-18-18 08:06PM  Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million PR Newswire
Jun-13-18 07:30AM  Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region PR Newswire
Jun-05-18 03:00AM  Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018 PR Newswire
May-16-18 08:35AM  What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltds (NYSE:BHVN) Earnings Trend? Simply Wall St.
May-15-18 04:15PM  Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results PR Newswire
May-09-18 07:35AM  Our Free Research Report on Biogen and More Biotech Stocks ACCESSWIRE
03:00AM  Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Apr-22-18 10:00PM  Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine PR Newswire
Apr-19-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon Enterprise, Tutor Perini, Waste Management, and Twenty-First Century Fox New Research Emphasizes Economic Growth GlobeNewswire
03:00AM  Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles PR Newswire
Apr-05-18 09:52AM  Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference PR Newswire
Apr-03-18 03:00AM  Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer PR Newswire
Mar-28-18 07:40AM  Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant ACCESSWIRE +8.18%
Mar-27-18 04:34PM  Canaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News Benzinga
06:47AM  Heres Whats Moving AnaptysBio and Biohaven Pharmaceutical Market Exclusive
Mar-26-18 04:13PM  Biohaven Craters By A Third On Migraine Drug Study Rivaling Allergan Investor's Business Daily -7.27%
12:31PM  Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today Motley Fool
12:19PM  Biohaven's IPO Roadshow Fantasy Meets Grimmer Reality Bloomberg
11:15AM  Biohaven plunges as investors pit migraine data against Allergan's drug Reuters
09:05AM  Biohaven shares drop 23% after migraine drug trial results MarketWatch
03:00AM  Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Mar-20-18 07:50PM  Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near? Simply Wall St.
Mar-13-18 10:42AM  Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks
Mar-12-18 03:00AM  Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors PR Newswire
Mar-06-18 04:30PM  Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results PR Newswire -7.59%
03:00AM  Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine PR Newswire
Mar-01-18 03:00AM  Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet PR Newswire
Feb-21-18 03:00AM  Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists PR Newswire
Feb-08-18 07:40AM  Analysis: Positioning to Benefit within Great Plains Energy, Flowers Foods, Hasbro, BIOHAVEN PHARM, Vonage, and NOW Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.58%
Feb-01-18 07:35AM  Investor Expectations to Drive Momentum within Park National, Loral Space and Communications, Allegiance Bancshares, BIOHAVEN PHARM, Equifax, and PayPal Discovering Underlying Factors of Influence GlobeNewswire -5.38%
Jan-18-18 03:00AM  Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist PR Newswire +7.58%
Jan-11-18 07:40AM  Wired News Biohaven Pharmaceutical Shares Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet ACCESSWIRE
Jan-09-18 03:00AM  Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet PR Newswire
Dec-21-17 03:00AM  Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder PR Newswire
Nov-27-17 03:00AM  Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant PR Newswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
03:00AM  Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Nov-16-17 03:00AM  Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine PR Newswire +5.93%
Nov-14-17 06:02PM  Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results PR Newswire
Nov-13-17 03:00AM  Biohaven Expands Finance Team With Appointment Of Senior Vice President PR Newswire
Nov-06-17 03:00AM  Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 PR Newswire
Nov-01-17 04:00AM  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with ALS Benzinga
03:00AM  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Oct-30-17 03:00AM  Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute PR Newswire
Oct-26-17 07:30AM  Corporate News Blog - US FDA Green Signals Clinical Investigation of Biohaven Pharma's Trigriluzole For Treatment Of OCD ACCESSWIRE
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Doogan DeclanDirectorApr 16Sale61.9250,0003,096,000926,002Apr 16 07:23 PM
Doogan DeclanDirectorApr 12Sale53.9238,8252,093,444976,002Apr 16 07:23 PM
Doogan DeclanDirectorMar 26Sale53.725,824312,8651,014,827Mar 26 06:30 PM
Bailey GregoryDirectorMar 25Option Exercise9.29107,500998,6752,582,601Apr 05 05:54 PM
CHILDS JOHN WDirectorMar 22Option Exercise9.29107,500998,675107,500Apr 05 05:53 PM
Doogan DeclanDirectorMar 22Sale53.665,351287,1351,020,651Mar 26 06:30 PM
Coric VladChief Executive OfficerMar 14Sale50.0231,8931,595,446440,000Mar 14 05:49 PM
Coric VladChief Executive OfficerMar 13Sale50.0216,145807,573455,783Mar 14 05:49 PM
Tilton JohnChief Commercial OfficerMar 12Option Exercise9.2910,00092,90010,000Mar 14 05:51 PM
Coric VladChief Executive OfficerMar 12Sale50.1551,9622,605,894464,045Mar 14 05:49 PM
Tilton JohnChief Commercial OfficerMar 12Sale50.1110,000501,1000Mar 14 05:51 PM
Doogan DeclanDirectorMar 01Sale47.1750,5952,386,5191,026,002Mar 01 05:59 PM
Doogan DeclanDirectorFeb 27Sale45.7123,3841,068,8831,076,597Mar 01 05:59 PM
Doogan DeclanDirectorFeb 27Sale45.0227,0451,217,520373,913Mar 01 05:59 PM
Doogan DeclanDirectorFeb 26Sale44.3120,896925,952400,958Feb 26 05:44 PM
Doogan DeclanDirectorFeb 25Sale45.4913,943634,2671,099,981Feb 26 05:44 PM
Doogan DeclanDirectorFeb 25Sale45.2520,434924,688421,854Feb 26 05:44 PM
Doogan DeclanDirectorFeb 22Sale44.7521,625967,682442,288Feb 26 05:44 PM
GREGORY JULIA PDirectorFeb 21Option Exercise23.6312,000283,56012,000Feb 25 04:40 PM
GREGORY JULIA PDirectorFeb 21Sale43.5612,000522,7200Feb 25 04:40 PM
Doogan DeclanDirectorFeb 19Sale45.511,40063,7141,113,924Feb 20 05:40 PM
Doogan DeclanDirectorFeb 15Sale45.4267830,7951,115,324Feb 20 05:40 PM
AGUIAR ERICDirectorFeb 04Option Exercise23.4717,609413,29117,609Feb 06 06:21 PM
Tilton JohnChief Commercial OfficerJan 10Option Exercise9.2910,50097,54510,500Jan 14 05:50 PM
Tilton JohnChief Commercial OfficerJan 10Sale37.6710,500395,5350Jan 14 05:50 PM
Doogan DeclanDirectorDec 03Sale41.9540,0001,678,0001,156,002Dec 06 04:26 PM
Gentile KimberlyVP of OperationsJun 15Option Exercise0.6112,5007,62512,500Jun 19 04:43 PM
Gentile KimberlyVP of OperationsJun 15Sale40.0212,500500,2500Jun 19 04:43 PM
Berman RobertChief Medical OfficerJun 12Sale37.3920,257757,443234,551Jun 12 04:12 PM
Berman RobertChief Medical OfficerJun 11Sale36.0975,4922,724,160250,827Jun 12 04:12 PM
Berman RobertChief Medical OfficerJun 08Sale36.018,406302,700320,692Jun 12 04:12 PM
Berman RobertChief Medical OfficerJun 07Sale36.012,50090,025327,427Jun 07 04:29 PM
Berman RobertChief Medical OfficerJun 06Sale36.0116,983611,558329,430Jun 07 04:29 PM
Berman RobertChief Medical OfficerJun 05Sale36.026,362229,131343,038Jun 07 04:29 PM
Doogan DeclanDirectorJun 05Sale35.4149,7631,762,2851,196,002Jun 06 04:19 PM
Doogan DeclanDirectorJun 04Sale35.0539,4531,382,8281,245,765Jun 06 04:19 PM
Doogan DeclanDirectorJun 01Sale35.0483,8982,939,7861,285,218Jun 01 05:29 PM
Coric VladChief Executive OfficerJun 01Sale35.0413,840484,954525,000Jun 01 05:26 PM
Coric VladChief Executive OfficerMay 31Sale35.0134,6191,212,011530,229Jun 01 05:26 PM
Doogan DeclanDirectorMay 31Sale35.0126,044911,8001,369,116Jun 01 05:29 PM
Engelhart JamesChief Financial OfficerMay 30Option Exercise0.615,0003,0505,000May 30 06:02 PM
Doogan DeclanDirectorMay 30Sale35.0084229,4701,395,160Jun 01 05:29 PM
Coric VladChief Executive OfficerMay 30Sale35.001,54153,935549,200Jun 01 05:26 PM
Engelhart JamesChief Financial OfficerMay 30Sale35.005,000175,0000May 30 06:02 PM
Berman RobertChief Medical OfficerMay 10Sale26.8235,000938,706348,000May 14 05:11 PM
Engelhart JamesChief Financial OfficerMay 07Sale27.672,50069,1750May 09 04:53 PM